TheEdgeResearch
Home / Stocks / ATTBF

Abattis Bioceuticals Corp. (ATTBF)

OTC Healthcare Medical - Pharmaceuticals
$0.00 ▲ +0.00%
Market Cap
$14,334
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
1.77
52-Wk Range
0.000001-0.00003
CEO
Robert G. Goodall
Country
CA
Currency
USD

Abattis Bioceuticals Corp. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $14,334. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -852.4%. Its beta of 1.77 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.01
Price / Sales
0.06
Price / Book
0.00
EV / EBITDA
0.15
Gross margin
67.6%
Operating margin
-1108.7%
Net margin
-852.4%
Return on equity
Debt / equity
0.14
Current ratio
0.73
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
48
IPO date
2014-05-29
Headquarters
Vancouver, BC, CA
About Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Comparable companies

Abattis Bioceuticals Corp. is most often compared with the following Healthcare names:

ARYXBIOIFCBGLCEOSINSDISOLFNUNZOWCPQEBRWIBFF
More research on ATTBF
ATTBF technical analysis ATTBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →